Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
Login Archives Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
    ×
  • Subscribe
Enter stock ticker or keyword
×
Join 100,000+ Like-Minded Investors Today
Twitter
JNJ

Johnson & Johnson

Stocks

The Moves to Make Now in Light of Apple's Hiring Slowdown

July 19, 2022 by Garrett Baldwin

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

Yesterday, we witnessed a short burst of momentum anchored by stronger banking earnings and improved expectations around rate hikes in July.And then Apple happened.

Read more...

IPOs

Why Cue Health Stock Could Cost You Money After the IPO

September 21, 2021 by Mike Stenger

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

Cue Health stock became the latest offering on Robinhood IPO Access this week.

But here's why the Cue Health IPO could cost retail investors long-term…

Read more...

Stocks

5 Best Dividend Stocks to Buy Now

August 24, 2021 by Money Morning Staff Reports

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

There’s no better time than now to invest in dividend stocks.

And some of the best dividend stocks that beat the S&P 500’s average yield of 2.00% can be found in the healthcare sector.

Global dividends fell by 12.2% in 2020 after the pandemic forced businesses and corporations to make a total of $220 billion in dividend cuts between the second and fourth quarters of 2020.

Since then, dividend payments jumped 26% to $471.7 billion.

And dividends paid to investors are expected to pay out $1.39 trillion by the end of the year.

We only have to look at one sector to find the best combination of yields and strong balance sheets.

Read more...

Stocks

This Cheap Stock Opens up a $100 Billion Medical Market

August 5, 2021 by Shah Gilani

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

Understandably, a lot of the world's medical and scientific firepower was focused on coronavirus vaccines this year.

But other advances in medicine have the potential to do even more for investors than the "vaccine stocks" did.

Shah's looking at a potential $100 billion medical market, and sizing up a $6 stock to play it…

Read more...

IPOs

Honest Company Stock: Why You Should Avoid It After the IPO

April 29, 2021 by Mike Stenger

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

Honest Company stock almost went public before.

Ironically, a lack of dishonesty put it on hold.

The Honest Company, founded by actress Jessica Alba, billed itself as "clean and sustainable," then it was found not to be so.

Five years later, it will trade on the Nasdaq under the ticker symbol "HNST." The company said on April 26 (Monday) that it would shoot for an IPO valuation of $1.5 billion, offering over 25 million shares in the range of $14 and $17.

But is Honest stock more of a buy today than it was then?

Stocks

This COVID-19 Vaccine Stock Has More Upside Than Pfizer or Moderna

March 27, 2021 by Michael A. Robinson

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

Developing effective vaccines against a deadly global pandemic is certainly bullish for a stock.

Indeed, Moderna and Pfizer shareholders have put away as much as 516% and 51% gains, respectively.

And when a lot of investors see this, they fear they’ve missed out.

Well, Michael’s here to assure you that you haven’t; not by a long shot.

And today, he’s got a vaccine stock you should put at the top of your “must-buy” list for the week ahead… .

Read more...

Trading Strategies

Why the Dow Jones Could Quickly Hit 35,000

November 19, 2020 by Greg Madison

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

The anticipation is palpable… and building fast. We've had three reports on extremely effective upcoming coronavirus vaccines, and each report practically blows the last one out of the water.

First we heard preliminary reports that Pfizer and BioNTech's revolutionary messenger RNA (mRNA) coronavirus vaccine was 90% effective. That was great… until yesterday morning, when the biotechs got back in touch to say the real figure was something closer to 95%. And in the middle, we've heard from Moderna, which is reporting its mRNA vaccine is 94.5% effective.

Every time, stocks have taken off like a shot at the news; vaccines have helped push the Dow back above its February 2020 highs.

Here's the thing… setting aside the six vaccines The New York Times reports are in limited use in China and Russia – about which there are many unanswered questions – there are at least nine more coronavirus vaccines deep in phase 3, large-scale efficacy trials.

And there are no less than 55 more candidates in earlier, phase 1 and 2 trials. Some of these vaccine candidates won't advance, but others almost certainly will – two have already.

That all this has happened in less than a year is an "Apollo moonshot"-like scientific achievement. But that's also a whole lot of concentrated upside potential that could flood the markets and push stocks to almost unthinkable highs.

So I asked Money Morning Chief Investment Strategist Shah Gilani what it all means for us investors…

Read more...

Trading Strategies

How to Trade Pfizer Stock for a 290% Profit in a Month

November 11, 2020 by Tom Gentile

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

Pfizer's recent news that their COVID-19 vaccine is 90% effective sent the market (and Pfizer's stock) soaring.

And while those who had already invested in the stock have made a nice return, Tom's going to show you the quick and easy way to almost quadruple your money on it…

Read more...

Trading Strategies

What to Do When the Market Sells Off Like This

October 27, 2020 by Shah Gilani

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

Driven by headlines, stocks were in a triple-digit freefall at midday Monday.

But the really important thing to understand is how and why the market leaders failed because it points to what we should be doing.

Here’s Shah to explain what’s happening and what you can do about it….

Read more...

Dow Jones

Dow Jones Today Could Take a Dip on Fresh Earnings Reports

October 13, 2020 by Garrett Baldwin

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

The Dow Jones today is down on the first major day of Q3 earnings reports.

Investors also await updates from Washington on a potential stimulus plan.

Markets remain in a holding pattern as Congress and the Trump administration continue to haggle over the size of a new deal.

Trump has said that he will approve a deal worth $1.8 trillion.

Democrats are hoping for a larger plan before the election.

Read more...

First
  • 1
  • 2
  • 3
  • …
  • 7
NextLast
Latest News

September 22, 2023 • By Shah Gilani

earnings
Why the Fed's "Higher for Longer" Message on Interest Rates is Bogus

September 22, 2023 • By Tom Gentile

This is the Top 'Worst-in-Breed' Stock Heading into October

September 21, 2023 • By Shah Gilani

earnings
The Best Auto Stocks to Buy (or Avoid) Right Now
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Penny Hawk Midday Momentum
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Quantum Data Profits Flashpoint Trader Darknet Alpha Accelerators Brutus Alerts Resource Traders Alliance L.A.U.N.C.H. Investor Rob Roy Trader Long-Term Equity Profits

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information